Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 2 years ago

Possible Interaction: Glucose and Exenatide

supplement:

Glucose

Research Papers that Mention the Interaction

Exenatide has been shown to reduce fasting and postprandial glucose in patients with type 2 diabetes, as well as provide sustained reductions in hemoglobin A 1c (HbA 1c).
Diabetes technology & therapeutics  •  2005  |  View Paper
The ability of glucose to facilitate β‐cell exocytosis was, however, significantly correlated with responses to Exendin 4.
Physiological reports  •  2020  |  View Paper
In MIN6 cells incubated with 25 mM glucose, exendin‑4 decreased the ratio of light chain 3 (LC3)‑II/I, which was accompanied by an increase in p62 protein.
Molecular medicine reports  •  2019  |  View Paper
Exendin 9–39 , a GLP-1 receptor antagonist, abolished the GPR120 induced effects on glucose and insulin following an intravenous glucose challenge.
PloS one  •  2017  |  View Paper
After subcutaneous administration, synthetic exendin-4 (exenatide) decreased postprandial concentrations of glucose and insulin, and fasting glucose levels in subjects with type 2 diabetes, and the effects lasted several hours.
Reviews on recent clinical trials  •  2007  |  View Paper
Thus, exendin 4 induces functional maturation of fetal beta-cells in response to glucose.
The Journal of clinical endocrinology and metabolism  •  2002  |  View Paper
Exendin-4 reduced fasting plasma glucose levels and reduced the peak change of postprandial glucose from baseline (exendin-4, 1.5 +/- 0.3 vs. saline, 2.2 +/- 0.3 mmol/l, P < 0.05).
American journal of physiology. Endocrinology and metabolism  •  2001  |  View Paper
We found that when the participants had an exendin 9 infusion at the same time as a glucose drink , they did not produce as much insulin and did not develop hypoglycaemia,” explains Gribble. “
Nature Reviews Endocrinology  •  2019  |  View Paper
EX decreased Hep‐IR (197 ± 28 to 130 ± 37; P = 0.02) and increased HGU of orally administered glucose (23 ± 4 to 232 ± 89 [μmol/min/L]/[μmol/min/kg]; P = 0.003) despite lower insulin (23 ± 5 vs. 41 ± 5 mU/L; P < 0.02).
Hepatology  •  2016  |  View Paper
FG was lower with exenatide than lispro (6.5 vs. 7.2 mmol/L; P = 0.002).
Diabetes Care  •  2014  |  View Paper
Show More